HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,022,000 | -37.3% | 38,906 | -36.0% | 0.02% | -38.9% |
| Q2 2020 | $1,630,000 | +2.5% | 60,806 | -31.2% | 0.04% | -5.3% |
| Q1 2020 | $1,591,000 | -41.0% | 88,441 | -41.9% | 0.04% | -13.6% |
| Q4 2019 | $2,697,000 | -96.1% | 152,103 | -96.6% | 0.04% | -96.0% |
| Q3 2019 | $69,576,000 | -16.5% | 4,485,933 | -7.5% | 1.09% | -9.6% |
| Q2 2019 | $83,344,000 | -26.2% | 4,851,229 | -30.8% | 1.20% | -16.2% |
| Q1 2019 | $112,862,000 | -14.5% | 7,010,066 | -22.3% | 1.44% | -18.8% |
| Q4 2018 | $132,067,000 | -21.2% | 9,027,164 | -2.2% | 1.77% | +5.4% |
| Q3 2018 | $167,680,000 | +20.3% | 9,228,399 | +11.7% | 1.68% | +30.5% |
| Q2 2018 | $139,354,000 | -13.2% | 8,260,476 | +0.8% | 1.29% | -10.6% |
| Q1 2018 | $160,489,000 | -9.7% | 8,192,378 | -6.6% | 1.44% | -3.8% |
| Q4 2017 | $177,783,000 | +2.3% | 8,775,073 | -12.3% | 1.50% | +0.8% |
| Q3 2017 | $173,803,000 | +27.8% | 10,005,952 | -5.7% | 1.48% | +23.5% |
| Q2 2017 | $136,007,000 | +0.9% | 10,608,993 | +2.0% | 1.20% | -0.9% |
| Q1 2017 | $134,789,000 | +27.0% | 10,400,388 | -3.2% | 1.21% | +23.8% |
| Q4 2016 | $106,105,000 | -5.5% | 10,739,413 | +15.6% | 0.98% | -0.1% |
| Q3 2016 | $112,223,000 | +58.8% | 9,290,024 | +13.4% | 0.98% | +49.8% |
| Q2 2016 | $70,691,000 | -14.6% | 8,191,274 | -6.3% | 0.66% | -7.0% |
| Q1 2016 | $82,820,000 | -45.0% | 8,745,524 | +0.7% | 0.70% | -43.1% |
| Q4 2015 | $150,497,000 | +36.9% | 8,684,184 | +6.1% | 1.24% | +33.2% |
| Q3 2015 | $109,911,000 | -49.6% | 8,184,003 | -15.3% | 0.93% | -46.0% |
| Q2 2015 | $218,183,000 | +86.1% | 9,662,663 | +17.7% | 1.72% | +74.2% |
| Q1 2015 | $117,215,000 | +67.0% | 8,208,323 | +12.8% | 0.99% | +51.1% |
| Q4 2014 | $70,195,000 | +11.2% | 7,274,065 | +4.9% | 0.65% | +0.5% |
| Q3 2014 | $63,109,000 | +3.0% | 6,935,095 | +11.9% | 0.65% | +3.5% |
| Q2 2014 | $61,253,000 | +49.2% | 6,199,685 | +91.8% | 0.63% | +33.9% |
| Q1 2014 | $41,065,000 | +26.3% | 3,232,154 | +49.1% | 0.47% | +21.8% |
| Q4 2013 | $32,501,000 | +4120.9% | 2,168,155 | +3006.7% | 0.38% | +3750.0% |
| Q3 2013 | $770,000 | – | 69,790 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |